Evicenter
MarkdownMedical informationP&T meetings
Deucrictibant (PHA121)

On-demand treatment of hereditary angioedema attacks

Also known as PHA-022121
Manufacturer
Pharvaris
Last updated
209 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of hereditary angioedema

Economic burden and healthcare resource utilization

16 evidence topics · 16 sources

Cost per attack treated on demand: Italian prospective cohort

“To explore treatment behaviours in a cohort of Italian patients with hereditary angioedema due to complement C1-inhibitor deficiency (C1-INH-HAE), and to estimate how effects and costs of treating attacks in routine practice differed across available on-demand treatments.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Cost analyses and survival analyses using attack-level data collected prospectively for 1 year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Overall, 133 of 167 patients (79.6%) reported 1508 attacks during the study period, with mean incidence of 11 attacks per patient per year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Only 78.9% of attacks were treated in contrast to current guidelines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The average cost per attack was €1183 (SD €789) resulting in €1.58 million healthcare costs during the observation period (€11 912 per patient per year).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Icatibant was 54% more expensive than pdC1-INH, whereas age, sex and prophylactic treatment were not associated to higher or lower costs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Emergency department and hospital use among users of intravenous C1 inhibitor: US claims

“The purpose of this retrospective study was to evaluate real-world treatment patterns of HAE-specific medications in the US and to assess their impact on healthcare resource utilization (HCRU).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This analysis used IMS PharMetrics PlusTM database records (2006–2014) of patients with HAE, ≥1 insurance claim for an HAE-specific medication, and continuous insurance enrollment for ≥3 months following the first HAE prescription claim.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Of 631 total patients, 434 (68.8%) reported C1-INH(IV) use; 396 (62.8%) reported using ecallantide and/or icatibant.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“There were 306 episodes of prophylactic use of C1-INH(IV) (defined by continuous refills averaging ≥1500 IU/week for ≥13 weeks) in 155 patients; use of ≥1 on-demand rescue medication was implicated during 53% (163/306) of those episodes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Sixty-eight (20.2%) of 336 C1-INH(IV) users eligible for the HCRU analysis were hospitalized at least once, and 191 (56.8%) visited the emergency department (ED).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This study was funded by CSL Behring.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Hospitalizations and emergency department visits with hereditary angioedema: nationally representative inpatient and emergency department samples, 2007
Attack-related medical visits and provider-administered on-demand treatment before and after berotralstat: US claims

“To evaluate all-cause, angioedema-related, and HAE attack–related medical visits and hospitalizations before and after initiation of berotralstat long-term prophylaxis (LTP) for patients with HAE in the United States.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“This retrospective pre-post analysis used Komodo’s Healthcare Map claims data to identify patients who initiated berotralstat (December 2020 to December 2022).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The study population included 260 patients treated with berotralstat (mean age = 39.7 years; 74.2% female).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“When stratifying by type of care setting, rates of HAE attack–related IP episodes decreased by 60% (from 0.28 to 0.11 PPY, P < 0.001) and OP/ED episodes decreased by 50% (from 1.46 to 0.74 PPY, P < 0.001) after berotralstat initiation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Following berotralstat initiation, the rates of on-demand medication administered by a provider decreased significantly by 32% (from 1.17 to 0.87 PPY, P = 0.002) among all patients” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Medical writing assistance was provided by Molly Gingrich, an employee of Groupe d’Analyze, Ltée, which received funding from BioCryst Pharmaceuticals for this study” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

Medical care, activity loss, and missed work or school: European patient survey

“The study was conducted in Spain, Germany, and Denmark to assess the real-world experience of HAE via a cross-sectional survey of HAE patients, including direct and indirect resource utilization during and between attacks for patients and their caregivers over the past 6 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Overall, 164 patients had an attack in the past 6 months and were included in the analysis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The most significant predictor of medical resource utilization was the severity of the last attack (OR 2.6; p < 0.001).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Among patients who sought medical care during the last attack (23%), more than half utilized the emergency department.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The last attack prevented patients from their normal activities an average of 4–12 hours.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“Among patients who were working or in school (n = 120), 72 provided work/school absenteeism data, resulting in an estimated 20 days missing from work/school on average per year; 51% (n = 84) indicated that HAE has hindered their career/educational advancement.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote

“The study was funded by ViroPharma SPRL-BVBA.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote